UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

Journal for immunotherapy of cancer, 2019-04, Vol.7 (1), p.105-105, Article 105

2019

Volltextzugriff (PDF)

Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics

Pharmaceutics, 2022-12, Vol.14 (12), p.2672

2022

Volltextzugriff (PDF)

Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics

Frontiers in immunology, 2024-08, Vol.15, p.1406804

2024

Volltextzugriff (PDF)

Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity

Frontiers in immunology, 2024-08, Vol.15, p.1406643

2024

Volltextzugriff (PDF)

HLAII peptide presentation of infliximab increases when complexed with TNF

Frontiers in immunology, 2022-09, Vol.13, p.932252

2022

Volltextzugriff (PDF)

Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

Journal of Virology, 2006-09, Vol.80 (17), p.8695-8704

2006

Volltextzugriff (PDF)

Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain

mAbs, 2012-11, Vol.4 (6), p.673-685

2012

Volltextzugriff (PDF)

Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes

Biology (Basel, Switzerland), 2023-09, Vol.12 (9), p.1265

2023

Volltextzugriff (PDF)

Recruiting the Immune System Against Disease: Lessons for Clinical and Systems Pharmacology

CPT: pharmacometrics and systems pharmacology, 2019-07, Vol.8 (7), p.436-439

2019

Volltextzugriff (PDF)

Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies

Proceedings of the National Academy of Sciences - PNAS, 2015-12, Vol.112 (50), p.15354-15359

2015

Volltextzugriff (PDF)

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling

Journal of Immunology Research, 2015-01, Vol.2015 (2015), p.1-14

2015

Volltextzugriff (PDF)

Nonclinical immunogenicity risk assessment of therapeutic proteins

Bioanalysis, 2019-09, Vol.11 (17), p.1631-1643

2019

Volltextzugriff (PDF)

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33

Hepatology (Baltimore, Md.), 2006-03, Vol.43 (3), p.592-601

2006

Volltextzugriff (PDF)

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products

Cellular immunology, 2015-06, Vol.295 (2), p.118-126

2015

Volltextzugriff (PDF)

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2020-02, Vol.34 (1), p.27-37

2020

Volltextzugriff (PDF)

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33

Journal of general virology, 2007-11, Vol.88 (11), p.2991-3001

2007

Volltextzugriff (PDF)

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2020-04, Vol.34 (2), p.253-253

2020

Volltextzugriff (PDF)

The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models

BMC systems biology, 2013-09, Vol.7 (1), p.95-95, Article 95

2013

Volltextzugriff (PDF)

Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets

Journal of general virology, 2005-09, Vol.86 (9), p.2507-2512

2005

Volltextzugriff (PDF)

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins

CPT: pharmacometrics and systems pharmacology, 2019-11, Vol.8 (11), p.773-776

2019

Volltextzugriff (PDF)

CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization

Cells (Basel, Switzerland), 2013-01, Vol.2 (1), p.19-42

2013

Volltextzugriff (PDF)

A review of quantitative modeling of B cell responses to antigenic challenge

Journal of pharmacokinetics and pharmacodynamics, 2014-10, Vol.41 (5), p.445-459

2014

Volltextzugriff (PDF)

Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry

Journal of innate immunity, 2014-01, Vol.6 (5), p.676-684

2014

Volltextzugriff (PDF)

Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry

Protein & cell, 2010-07, Vol.1 (7), p.664-674

2010

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(37)
Buchkapitel
(1)

Sprache

Englisch
(38)

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Humans
(22)
Immunology
(13)
Immunogenicity
(9)
Animals
(7)
Hepatitis C Virus
(7)
Pharmacology & Pharmacy
(7)
Antibodies
(6)
Biological And Medical Sciences
(6)
Dendritic Cells
(6)
Immune Response
(6)
Lymphocytes
(6)
Antigens
(5)
Biological Products
(5)
Immune System
(5)
Peptides
(5)
Proteins
(5)
Risk Assessment
(5)
Viral Envelope Proteins - Metabolism
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics

Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of Biotherapeutics

Development and characterization of dendritic cell internalization and activation assays contributing to the immunogenicity risk evaluation of biotherapeutics

Internalization of therapeutic antibodies into dendritic cells as a risk factor for immunogenicity

HLAII peptide presentation of infliximab increases when complexed with TNF

Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding

Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain

Expanding the MAPPs Assay to Accommodate MHC-II Pan Receptors for Improved Predictability of Potential T Cell Epitopes

Recruiting the Immune System Against Disease: Lessons for Clinical and Systems Pharmacology

Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling

Nonclinical immunogenicity risk assessment of therapeutic proteins

Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33

Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models

Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins

CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization

A review of quantitative modeling of B cell responses to antigenic challenge

Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry

CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery

Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry

Suchergebnisse filtern